Answers are grounded in this paper and cite their sources.
To investigate whether transcriptional factor EB (TFEB) participates in amyloid-β(1-42) (Aβ(1-42))-induced pathogenesis of Alzheimer's disease (AD) and its underlying mechanisms. Three-month-old and 8-month-old transgenic APP/PS1 AD mice and age-matched wild mice were used in this study. We found that the 8-month-old AD animals presented significantly higher deposition of Aβ(1-42) and expression of TFEB and its targeted proteins, such as LAMP-1 and cathepsin D, and autophagy-associated LC3-II and p62 in brain tissues than in others. In an in vitro study, TFEB overexpression rescued autophagic flux that blocked by Aβ(1-42) and the degradation of the absorbed Aβ(1-42), relieved Aβ(1-42)-mediated induction of overloaded autophagy. In addition, TFEB overexpression enhanced cathepsin D expression and activity, restored Aβ(1-42)-disturbed acid environment of lysosome, and promoted the fusion of autophagosomes with lysosomes. Furthermore, TFEB upregulation reduced Aβ(1-42)-induced production of malondialdehyde, oxidative carbonyl proteins, and reactive oxygen species (ROS) and cell apoptosis mainly dependent on the removal of Aβ(1-42) by the autophagy-lysosome pathway. TFEB overexpression alleviated AD progression by reducing Aβ accumulation through regulating the autophagy-lysosome pathway and reducing Aβ-induced ROS production and cell apoptosis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: